Skip to main content

Table 2 Medication use (paracetamol, dexamethasone, and NSAIDs) in Cases and Controls

From: Non-steroidal anti-inflammatory drugs and the risk of a second hip fracture: a propensity-score matching study

Variables

Cases (n = 94)

Controls (n = 461)

P Value

Paracetamol, no. (%)

34 (35.8)

83 (18.1)

0.026*

  MDDa, mg (SD)

605.6 (103.4)

496.0 (127.9)

0.009*

Aspirin, no. (%)

9 (9.9)

46 (10.0)

0.491

  MDD, mg (SD)

105.6 (57.9)

101.2 (53.9)

0.569

Diclofenac, no. (%)

39 (41.7)

71 (15.4)

<0.001*

  MDD, mg (SD)

206.9 (59.4)

116.1 (99.1)

<0.001*

Ibuprofen, no. (%)

26 (28.1)

93 (20.1)

<0.001*

  MDD, mg (SD)

439.9 (115.9)

257.6 (85.0)

<0.001*

Naproxen, no. (%)

7 (7.4)

30 (6.5)

0.643

  MDD, mg (SD)

485.2 (184.9)

451.0 (150.1)

0.583

Nabumetone, no. (%)

8 (9.0)

47 (10.1)

0.217

  MDD, mg (SD)

1055.7 (479.3)

1014.7 (609.7)

0.506

Etodolac, no. (%)

13 (13.6)

54 (11.8)

0.416

  MDD, mg (SD)

552.0 (50.1)

590.5 (33.9)

0.563

Celecoxib, no. (%)

22 (23.1)

44 (9.5)

<0.001*

  MDD, mg (SD)

305.3 (98.8)

198.2 (100.1)

<0.001*

Rofecoxib, no. (%)

11 (11.6)

57 (12.3)

0.086

  MDD, mg (SD)

70.6 (6.6)

75.7 (9.8)

0.057

Dexamethasone, no. (%)

37 (39.4)

76 (16.5)

<0.001*

  MDD, mg (SD)

9.8 (7.5)

4.0 (3.9)

<0.001*

  1. a MDD, mean daily dose
  2. * P value < 0.05 is significant and all analysis was done by logistic regression model in SAS 9.2